UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 479

Sortiert nach

Head and neck tumours in Ghanaian children. A 20 year review

International journal of oral and maxillofacial surgery, 2012-11, Vol.41 (11), p.1378-1382

2012

Volltextzugriff (PDF)

Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

European neuropsychopharmacology, 2016-10, Vol.26, p.S546-S547

2016

Volltextzugriff (PDF)

Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: An analysis of phase III clinical trial hospital data

European psychiatry, 2016-03, Vol.33 (S1), p.S265-S266

2016

Volltextzugriff (PDF)

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S548-S549

2016

Volltextzugriff (PDF)

Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases

International journal of clinical practice (Esher), 2014-12, Vol.68 (12), p.1514-1522

2014

Volltextzugriff (PDF)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

Neuropsychiatric disease and treatment, 2013-01, Vol.9 (default), p.1381-1392

2013

Volltextzugriff (PDF)

A specialized home care intervention improves survival among older post-surgical Cancer patients

Journal of the American Geriatrics Society (JAGS), 2000-12, Vol.48 (12), p.1707-1713

2000

Volltextzugriff (PDF)

Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study

European psychiatry, 2015-03, Vol.30, p.272-272

2015

Volltextzugriff (PDF)

Maxillofacial and concomitant injuries in multiple injured patients at Korle Bu Teaching Hospital, Ghana

West African journal of medicine, 2014-01, Vol.33 (1), p.51

2014

Volltextzugriff (PDF)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

Neuropsychiatric disease and treatment, 2013-01, Vol.9 (default), p.721-730

2013

Volltextzugriff (PDF)

An unusually large spindle cell sarcoma of the tongue in a male child

Ghana medical journal, 2013-12, Vol.47 (4), p.208-210

2013

Volltextzugriff (PDF)

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

The New England journal of medicine, 2005-09, Vol.353 (11), p.1114-1123

2005

Volltextzugriff (PDF)

Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

Patient preference and adherence, 2020-01, Vol.14, p.1093-1102

2020

Volltextzugriff (PDF)

Melanoma-associated expression of transforming growth factor-beta isoforms

The American journal of pathology, 1996-06, Vol.148 (6), p.1887-1894

1996

Volltextzugriff (PDF)

P.2.e.018 Randomized, placebo, active-controlled study of paliperidone extended-release (ER) for acute manic and mixed episodes in bipolar I disorder

European neuropsychopharmacology, 2008, Vol.18, p.S369-S369

2008

Volltextzugriff (PDF)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Neuropsychiatric disease and treatment, 2019-05, Vol.15, p.1365-1379

2019

Volltextzugriff (PDF)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

Patient preference and adherence, 2021-01, Vol.15, p.2239-2248

2021

Volltextzugriff (PDF)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Neuropsychiatric disease and treatment, 2020-01, Vol.16, p.1533-1542

2020

Volltextzugriff (PDF)

Neonatal neurological examination in a resource-limited setting: What defines normal?

European journal of paediatric neurology, 2020-11, Vol.29, p.71-80

2020

Volltextzugriff (PDF)

Effect of two long-acting treatments, the paliperidone palmitate 1-month and 3-month formulations on caregiver burden in European patients with schizophrenia

European psychiatry, 2017-04, Vol.41 (S1), p.S198-S198

2017

Volltextzugriff (PDF)

P.3.d.029 - Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

European neuropsychopharmacology, 2016-10, Vol.26, p.S546-S547

2016

Volltextzugriff (PDF)

P.3.d.033 - Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S548-S549

2016

Volltextzugriff (PDF)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Neuropsychiatric disease and treatment, 2019-01, Vol.15, p.587-602

2019

Volltextzugriff (PDF)

Chronic subdural haematoma: review of 96 cases attending the Korle Bu Teaching Hospital, Accra

West African journal of medicine, 2005-10, Vol.24 (4), p.283-286

2005

Volltextzugriff (PDF)

Hemispheric brain abscess: a review of 46 cases

West African journal of medicine, 2006-04, Vol.25 (2), p.126-129

2006

Volltextzugriff (PDF)

1 – 25 von 479

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(372)
Mit Volltextzugriff
(422)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Head and neck tumours in Ghanaian children. A 20 year review

Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: An analysis of phase III clinical trial hospital data

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

A specialized home care intervention improves survival among older post-surgical Cancer patients

Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study

Maxillofacial and concomitant injuries in multiple injured patients at Korle Bu Teaching Hospital, Ghana

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose

An unusually large spindle cell sarcoma of the tongue in a male child

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

Melanoma-associated expression of transforming growth factor-beta isoforms

P.2.e.018 Randomized, placebo, active-controlled study of paliperidone extended-release (ER) for acute manic and mixed episodes in bipolar I disorder

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Neonatal neurological examination in a resource-limited setting: What defines normal?

Effect of two long-acting treatments, the paliperidone palmitate 1-month and 3-month formulations on caregiver burden in European patients with schizophrenia

P.3.d.029 - Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

P.3.d.033 - Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Chronic subdural haematoma: review of 96 cases attending the Korle Bu Teaching Hospital, Accra

Hemispheric brain abscess: a review of 46 cases

Suchergebnisse filtern